ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities. Data are provided ‘as is’ for informational purposes only and are not intended for trading purposes. Data may be intentionally delayed pursuant to supplier requirements. Rocket’s gene therapy, RP-1501, is designed to treat Danon disease, a fatal inherited disease that often leads to death in men by age 20 and in women by age 40. According to Rocket, Danon affects between 15,000 to 30,000 patients in the U.S. and Europe.
Dow Jones Industrial Average, S&P 500, Nasdaq, and Morningstar Index (Market Barometer) quotes are real-time. This site is protected by reCAPTCHA and the Google
Terms of Service apply. We’d like to share more about how we work and what drives our day-to-day business. Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.
Stock , RCKT
The Duravelo-2 study will assess BT8009 in untreated metastatic bladder cancer (Cohort 1) and previously treated metastatic bladder cancer (Cohort 2). Two doses of BT8009 plus standard Keytruda (pembrolizumab) regimen will be initially evaluated in Cohort 1. BT8009 plus pembrolizumab will be evaluated against chemotherapy after an optimal dose is selected. Two doses of BT8009 as monotherapy will be initially studied in Cohort 2. An additional arm of BT8009 plus standard pembrolizumab regimen will be added after the selection of the optimal dose.
Management reiterated its previously announced revenue guidance of $8-$15 billion in product sales from its respiratory franchise by 2027. 12 Wall Street research analysts have issued 12-month target prices for Rocket Pharmaceuticals’ shares. Their RCKT share price forecasts range from $34.00 to $75.00. On average, they anticipate the company’s stock price to reach $49.45 in the next year. This suggests a possible upside of 132.9% from the stock’s current price. View analysts price targets for RCKT or view top-rated stocks among Wall Street analysts.
See More Zacks Research for These Tickers
Rocket said it expects to receive $175 million from the public offering. 12 Wall Street research analysts have issued «buy,» «hold,» and «sell» ratings for Rocket Pharmaceuticals in the last twelve months. The consensus among Wall Street research analysts is that investors should «buy» RCKT shares. Shares of Rocket Pharmaceuticals (RCKT 9.56%) were up by more than 36% as of 11 a.m.
More value-oriented stocks tend to represent financial services, utilities, and energy stocks. These are established companies that reliably pay dividends. According to 11 analysts, the average rating for RCKT stock is «Strong Buy.» The 12-month stock price forecast is $49.55, which is an increase of 114.87% from the latest price. The technique has proven to be very useful for finding positive surprises.
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.32% per year. These returns cover a period from January 1, 1988 through July 31, 2023.
Get stock recommendations, portfolio guidance, and more from The Motley Fool’s premium services. Jim Halley has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The small trial will look at the effectiveness and safety of RP-A501 in a dozen Danon disease patients. Founded in 1993 by brothers Tom and David Gardner, The Motley Fool helps millions of people attain financial freedom through our website, podcasts, books, newspaper column, radio show, and premium investing services. The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023.
Shares of Rocket Pharmaceuticals RCKT, +0.17% gained 2.3% premarket on Thursday after the late-stage biotech company said the U.S. Food and Drug Administration granted fast-track and orphan-drug desig… © 2023 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions.
RCKT’s historical performance
against its industry peers and the overall market.
- Analysts are wholeheartedly bullish on the security, with all 12 in coverage carrying a «buy» or better rating.
- Recent stocks from this report have soared up to +178.7% in 3 months – this month’s picks could be even better.
- The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.
Rocket has secured an ICD-10 code from CMS for LAMP2 deficiency in Danon Disease. The disease affects an estimated 15,000 to 30,000 patients in the U.S. and Europe. The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%. An industry with a larger percentage of Zacks Rank #1’s and #2’s will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4’s and #5’s. Plus, RCKT info will be updated daily in your Zacks.com Portfolio Tracker – also free.
Meanwhile, discussions with the FDA about the design of the confirmatory trial for previously treated metastatic bladder cancer are ongoing. Analysts are wholeheartedly bullish on the security, with all 12 in coverage carrying a «buy» or better rating. Meanwhile, short interest represents 10.1% of the stock’s available float, and would take 12 days to cover, at RCKT’s average pace of trading. In response, RCKT’s typically quiet options pits are bursting with activity. So far, 5,309 calls and 2,285 puts have been exchanged, which is 63 times the average intraday volume. The September 22.50 call is the most popular, with new positions being bought to open there.
The formula for calculating dividend yield is to divide the annual dividend paid per share by the stock price. Rocket Pharmaceuticals also announced an equity offering of $175 million, including 7.8 million shares at $16.00 per share and https://1investing.in/ pre-funded warrants to purchase 3.1 million shares at $15.99 per pre-funded warrant. Rocket Pharmaceuticals reaches alignment with the Food and Drug Administration regarding its global Phase 2 trial for a treatment of Danon disease.
Bausch Health Companies
Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations.
Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Moderna and its partner Merck initiated a pivotal phase III study on its investigational individualized neoantigen therapy mRNA-4157 in melanoma patients. Management announced that it has completed enrolling participants in a late-stage study on mRNA-1283, a next-generation refrigerator-stable COVID-19 vaccine. Moderna expects to launch 15 new products, including four products in rare diseases, over the next five years. The company expects to bring in an additional $10 billion to $15 billion in annual sales of cancer, rare and latent disease therapies by 2028.
Patients with the rare disease are missing the DNA instructions needed for the body to make the LAMP2 protein, which is crucial to lysosome function and cellular recycling. Danon can cause heart muscle disease, muscle weakness, intellectual disability, and eye disease, and can also affect the lungs and liver. Rocket Pharmaceuticals’ stock is owned by a number of institutional and retail investors. Insiders that own company stock include Gaurav Shah, Gotham Makker, John Militello, Jonathan David Schwartz, Kinnari Patel and Rtw Investments, Lp. Dividend yield allows investors, particularly those interested in dividend-paying stocks,
to compare the relationship between a stock’s price and how it rewards stockholders through dividends.
Upgrade to MarketBeat All Access to add more stocks to your watchlist. One share of RCKT stock can currently be purchased for approximately $21.23. Compare
RCKT’s historical performance
against its industry peers and the overall market.
Rocket Pharmaceuticals’ stock was trading at $19.57 at the start of the year. Since then, RCKT stock has increased by 8.5% and is now trading at $21.23. Click the link below and we’ll send you MarketBeat’s guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.
Additional secondary endpoints will include natriuretic peptides, Kansas City Cardiomyopathy Questionnaire, New York Heart Association class, event-free survival to 24 months and treatment emergent safety events. These endpoints could support full approval with longer-term follow-up. A global natural history study will serve as an external comparator and run concurrently with the mid-stage study.
Our Quantitative Research team models direct competitors or comparable companies
from a bottom-up perspective to find companies describing their business in a
Zacks Earnings ESP (Expected Surprise Prediction) looks to find companies that have recently seen positive earnings estimate revision activity. The idea is that more recent information is, generally speaking, more accurate and can be a better predictor of the future, which can give investors an advantage in earnings season. scope of financial accounting As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style. The Style Scores are a complementary set of indicators to use alongside the Zacks Rank.
Rocket has several other genetic therapies in its pipeline. RP-L102 is being developed to treat Fanconi anemia, a rare DNA repair disorder that can cause bone marrow failure, predisposition to cancer, and early death. RP-L201 is being tested to treat leukocyte adhesion deficiency, a rare genetic immune disorder that can lead to frequent infections. RP-L301 is designed to treat pyruvate kinase deficiency, which can lead to chronic anemia. RP-A601 is being developed for plakophilin-2 related arrhythmogenic cardiomyopathy, another rare genetic disorder.
The late-stage pharmaceutical company said it had reached an agreement with the Food and Drug Administration regarding a phase 2 trial for a Danon disease therapy. The scores are based on the trading styles of Value, Growth, and Momentum. There’s also a VGM Score (‘V’ for Value, ‘G’ for Growth and ‘M’ for Momentum), which combines the weighted average of the individual style scores into one score. You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security.
It allows the user to better focus on the stocks that are the best fit for his or her personal trading style. Volatility profiles based on trailing-three-year calculations of the standard deviation of service investment returns. Our experts picked 7 Zacks Rank #1 Strong Buy stocks with the best chance to skyrocket within the next days. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here. In a separate phase I/II head-to-head study, mRNA-1010 also elicited a higher antibody response across all four A and B strains over Fluzone HD.
Data from the P303 study is expected to support Moderna’s filing for mRNA-1010. The remaining weeks of December are chock-full of clinical trial results and FDA approval decisions that savvy investors can take advantage of. Analysts Sami Corwin and Brooke Schuster write that the data from the Phase 1 study of RP-A501 de-risks the pivotal trial. Analysts say a tough 2022 has left these small-cap stocks priced for outperformance in the new year and beyond. Health care stocks are trying to make a comeback and these three small-cap biopharma companies are leading the charge in some ways. The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.